Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ARUK 2022 | Next steps for research into the NLRP3 inflammasome in dementia

Sarah Ryan • 1 Mar 2022
ARUK 2022
Alzheimer’s Disease Dementia Frontotemporal Dementia

Sarah Ryan, PhD, University of Manchester, Manchester, UK, discusses the future of research into the NLRP3 inflammasome in frontotemporal dementia and Alzheimer’s disease. Areas of investigation include moving from in vitro to in vivo studies and repurposing NLRP3-targeted drugs, such as mefenamic acid, which are already approved for use in other diseases. This interview took place at the Alzheimer’s Research UK Conference 2022 in Brighton, UK.

More from Sarah Ryan

0:57
Dipeptide repeat proteins and the NLRP3 inflammasome in FTD
Sarah Ryan • 1 Mar 2022
0:48
Functions of the inflammasome
Sarah Ryan • 1 Mar 2022

Related Videos

3:58
Promising FONLISA test for ultrasensitive detection of plasma NfL in Alzheimer’s disease
Madison Honey • 7 Mar 2024
4:12
Updates in Alzheimer’s treatment: the potential of NSC001
Manfred Windisch • 6 Mar 2024
4:44
Influence of genetic risk for psychiatric disorders on dementia
Jenna Najar • 6 Mar 2024
2:31
Barriers to dementia treatment: awareness, accessibility, and affordability
Paola Barbarino • 23 Mar 2024
The content of VJDementia is intended for healthcare professionals